17 Dec 2018 07:00
RNS Number : 5484K
Immupharma PLC
17 December 2018
17 December 2018
ImmuPharma PLC
("ImmuPharma" or the "Company")
APPOINTMENT OF NOMINATED ADVISOR
ImmuPharma PLC (LSE: IMM), the specialist drug discovery and development company is pleased to announce the appointment of SPARK Advisory Partners Limited ("SPARK") as the Company's Nominated Advisor ("NOMAD"), with immediate effect.
Commenting on the appointment, ImmuPharma's Chairman, Tim McCarthy, said:
"I am delighted to announce the appointment of SPARK as the Company's NOMAD. We look forward to working with the team going forward, alongside our joint brokers, Stanford Capital Partners and SI Capital."
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014. ("MAR")
For further information please contact: ImmuPharma plc (www.immupharma.com) | + 44 (0) 207 152 4080 | Tim McCarthy, Chairman | | Lisa Baderoon, Head of Investor Relations | + 44 (0) 7721 413496 | SPARK Advisory Partners Limited (NOMAD) Neil Baldwin Vassil Kirtchev Stanford Capital Partners (Joint Broker) Patrick Claridge, John Howes SI Capital (Joint Broker) Nick Emerson | +44 (0) 203 368 8974 +44 (0) 203 815 8880 +44 (0) 1483 413500 | About SPARK Advisory Partners Limited SPARK Advisory Partners was established in January 2012 by its founding partners to provide product independent corporate finance advice to mid-market companies, owner managers and shareholders.SPARK is owned by its partners who have worked together for many years. The team has a broad cross section of skills and transaction experience, encompassing M&A, private equity, public capital raisings and debt advisory services. For more information go to: www.sparkadvisorypartners.com | | | | | | | | | | |
|
| | |
| | | |
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
APPBBBDDCBBBGIS
Immupharma (IMM)